Ads
related to: new weight loss drug approvedA Prescription Option For Adults With Obesity, Discover How It May Help You. Access Patient Resources & Support Including Quick Start Guide & Savings Information.
- Dosing Information
View Dosing Information & Support
Including Our Quick Start Guide.
- Understanding Obesity
Learn What Obesity Is, What
Causes It & How It Is Addressed.
- Getting Started
Find Tips For Getting Started
On Your Weight-Loss Journey.
- Patient Support
Get A Personalized Patient
Support Program, Learn More.
- Dosing Information
noom.com has been visited by 10K+ users in the past month
Daily Reminders and Weight Tracking to Help You Stay Accountable to Your Weight Goals. Set Your Timeline, See Your Plan, Start Your Calorie Budget. Get Better Results with Noom.
Start The Conversation With Your Obesity Patients, View Guide To Get Started. Obesity Is A Chronic Disease, Find Resources To Help Prevent Weight Regain.
Don't let cravings derail your Weight Loss goals. Take Control with an FDA-Approved WL Rx! Keep the weight off this time w/ FDA-Approved Prescription Weight Loss Pills. Learn More.
Taking A Weight Loss Drug Or Shot? Atkins™ Products Help Get Key Nutrients Your Body Needs. Get Tips For Eating On Weight Loss Drugs & Learn How Atkins™ Can Help You.
Search results
People also ask
Is zepbound the most effective weight loss drug ever?
How much does Eli Lilly weight loss medicine cost?
How effective is pharmaceutical obesity treatment?
Is mounjaro a weight loss drug?
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved an obesity drug from the company Eli Lilly that will be a direct competitor to the wildly popular Wegovy. The drug is called tirzepatide...
Jun 26, 2023 · CNN — An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss...
- Meg Tirrell
- 2 min
Nov 8, 2023 · Zepbound is a once-weekly injection that reduces appetite and food intake by activating hormone receptors. It is approved for adults with obesity or overweight and at least one weight-related condition, but it has side effects and warnings.
Nov 8, 2023 · The Food and Drug Administration on Wednesday approved Zepbound, a new weight loss drug from drugmaker Eli Lilly that was shown in clinical trials to help people lose up to 52 pounds in 16...
- Berkeley Lovelace Jr.
- Overview
- How well does Zepbound work?
- Who is eligible to take Zepbound?
- How much will I have to pay for Zepbound?
- What are the risks of taking weight loss drugs?
- When will Zepbound be available?
A new weight loss drug has been approved that promises to be the most effective medication yet. How is Zepbound, the weekly injectable drug that’s expected to be available shortly after Thanksgiving, different from other weight loss medications?
Zepbound, from drugmaker Eli Lilly, belongs to a new class of medications, called GLP-1 agonists, that have skyrocketed in popularity in the U.S. in recent years. Novo Nordisk's Ozempic and Wegovy and Lilly’s Mounjaro are the same type of drugs.
Ozempic and Mounjaro are prescribed to help people with diabetes control their blood sugar levels.
Wegovy and Zepbound are for people who don’t already have diabetes but whose excess weight puts them at risk of health complications.
In clinical trials, Zepbound helped people lose, on average, 52 pounds, nearly rivaling the weight loss results achieved with bariatric surgery, according to Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina.
Here’s what you need to know about Lilly’s new drug.
The active ingredient in Zepbound is tirzepatide, which mimics a hormone that helps reduce food cravings. The diabetes medication Mounjaro also contains tirzepatide.
Ozempic and Wegovy contain semaglutide, an ingredient that can suppress appetite by mimicking a hormone that signals to the brain when a person is full.
What makes tirzepatide even more helpful is it also imitates a second hormone, called GIP, which — along with reducing appetite — may also improve how the body breaks down sugar and fat, helping to amplify the weight loss effects.
In a phase 3 clinical trial, a 15-milligram dose of tirzepatide, the highest dose, led to an average weight loss of 22.5% body weight, or about 52 pounds. The participants in the study had obesity or were overweight with at least one weight-related condition.
At lower doses, patients also lost weight: At a 10 mg dosage, the average weight loss was about 21.4%, or about 48 pounds; at 5 mg, patients achieved an average weight loss of around 16%, or about 35 pounds.
In similar trials, semaglutide was shown to reduce body weight by around 15%, or about 34 pounds, after 68 weeks.
The Food and Drug Administration approved Zepbound for use by adults with a body mass index, or BMI, of at least 30 or a BMI of 27 or more if a patient also has another weight-related condition, such as high blood pressure, heart disease or obstructive sleep apnea.
The agency said the drug should be used along with a reduced calorie diet and exercise.
People who are prescribed the medication should not take another GLP-1 agonists, like Ozempic or Wegovy.
Zepbound is only approved for adults 18 and older. Wegovy is approved for people 12 and older. On Zepbound’s label, the FDA notes that the safety and effectiveness of Zepbound have not yet been established in teens or adolescents.
Lilly has priced Zepbound at about $1,060 for a month’s supply, and while it’s less than Wegovy, which is priced at around $1,300, both drugs may be too expensive for many people who are eligible. Insurance companies often refuse to cover weight loss medications. Medicare, by law, does not cover them.
“Cost will be a barrier,” said Dr. Nishant Shah, a preventative cardiologist at Duke University Medical Center in Durham, North Carolina.
Eli Lilly said patients can sign up on its website for a copay, or a discount card program that could help lower the cost of the drug.
The company also said that people who are able to get Zepbound through commercial insurance may be eligible to pay as low as $25 for a one-month or three-month supply. People who are commercially insured but do not have coverage for Zepbound may be eligible to pay as low as $550 for a one-month prescription of Zepbound, according to the company.
Zepbound, like other GLP-1 agonists, can cause uncomfortable side effects, including gastrointestinal problems.
According to the FDA’s drug label, side effects include:
•Nausea
•Diarrhea
•Vomiting
•Constipation
Doctors in the U.S. should be able to prescribe Zepbound sometime after Thanksgiving, although Lilly executives didn’t say how many doses would be available this year.
Given the anticipated high demand, it’s unknown what kinds of shortages people who want the drug will face. The supply is expected to increase through 2024, Lilly said during the Wednesday briefing.
- Berkeley Lovelace Jr.
Nov 8, 2023 · An obesity drug called Zepbound won approval for use in adults from the Food and Drug Administration Wednesday, ushering in a new rival to Novo Nordisk's blockbuster Wegovy. Eli Lilly & Co.,...
Nov 8, 2023 · CNN. The US Food and Drug Administration approved the type 2 diabetes drug tirzepatide for use in chronic weight management Wednesday, making official the use of a medicine already widely...
Ads
related to: new weight loss drug approvedA Prescription Option For Adults With Obesity, Discover How It May Help You. Access Patient Resources & Support Including Quick Start Guide & Savings Information.
Daily Reminders and Weight Tracking to Help You Stay Accountable to Your Weight Goals. Set Your Timeline, See Your Plan, Start Your Calorie Budget. Get Better Results with Noom.
Don't let cravings derail your Weight Loss goals. Take Control with an FDA-Approved WL Rx! Keep the weight off this time w/ FDA-Approved Prescription Weight Loss Pills. Learn More.
